Spots Global Cancer Trial Database for 68-Ga-FAPI PET Imaging in Malignancy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: 68-Ga-FAPI PET Imaging in Malignancy

Official Title: 68Ga-FAPI PET Imaging in Malignancy

Study ID: NCT04023240

Conditions

Cancer

Interventions

68Ga-FAPI

Computed Tomography (CT) scan

Positron Emission Tomography (PET) scan

Study Description

Brief Summary: This feasibility trial studies the use of gallium-68 (68Ga)-FAPI as the imaging agent for positron emission tomography (PET)/computed tomography (CT), collectively PET/CT, in patients with various cancers. PET uses a radioactive substance called 68Ga-FAPI, which attaches to cancer activated fibroblasts. The PET scanner takes pictures that capture where the radioactive drug is "lighting up" and attaching to tumor cells, which may help doctors recognize differences between tumor and healthy tissue. CT uses X-rays to make a picture of areas inside the body. Using 68Ga-FAPI in diagnostic procedures, such as PET/CT, may allow doctors to identify smaller tumors than standard imaging.

Detailed Description: PRIMARY OBJECTIVE: To assess feasibility and biodistribution of PET imaging in malignancy using 68Ga-FAPI. OUTLINE: Patients receive 68Ga-FAPI intravenously (IV) and then undergo PET/CT approximately 1 hour later. After completion of study, patients are followed up at 24-72 hours.